Abstract:This paper investigated the hypoglycemic effect of Ganoderma lucidum spirulina compound capsules on type II diabetes mellitus（T2DM）mice.A T2DM mouse model was established using high-calorie feed combined with intraperitoneal injection of streptozotocin. The mice were then randomly divided into control，model，low-dose，medium-dose，and high-dose groups. Those in the intervention groups continuously received G. lucidum spirulina compound capsules for four weeks. The body weight，organ index，and blood-related indexes of mice were measured，and histopathologic sections of liver，pancreas and cecum were observed.The results showed that low，medium and high doses（equivalent to 5，10 and 30 times the recommended dosage for humans，respectively）of G.lucidum spirulina compound capsules improved the organ index，blood glucose and glucose tolerance of T2DM mice to different degrees.Histopathologic sections revealed significant recovery in hepatocyte volume with neat arrangement as well as decreased vacuoles. This improvement indicated a reduction in hepatocyte damage and inflammation.Furthermore，an increase in the dosage resulted in clearer and more orderly edges of pancreatic islet cells. The three dosages markedly improved the morphology of the outer membrane，muscle layer，mucosa，and villi of cecum tissue. However，there were a few rounded villi in low- and medium-dose groups. In conclusion，the low，medium，and high doses of G. lucidum spirulina compound capsules effectively regulated the glucose and lipid metabolism in T2DM mice，contributing to maintaining normal blood glucose.